Modeling Secondary Iron Overload Cardiomyopathy with Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Area of Science:

• Cardiology
• Stem Cell Biology
• Pharmacology

Background:

• Iron overload cardiomyopathy (IOC) results from excessive cardiac iron, leading to heart failure.
• Mechanisms of iron-induced cardiac injury and cardiomyocyte iron accumulation remain unclear.
• Understanding these processes is crucial for developing effective treatments.

Purpose of the Study:

• To model iron overload cardiomyopathy (IOC) using human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs).
• To investigate the mechanisms of iron-related cardiac injury in iPSC-CMs.
• To screen for potential therapeutic agents to rescue IOC phenotypes.

Main Methods:

• Generation of human iPSC-CMs.
• Exposure of iPSC-CMs to excess iron to model IOC.
• Assessment of cardiac function, oxidative stress, and calcium kinetics.
• Drug screening using ebselen as a candidate therapeutic.

Main Results:

• Iron-exposed iPSC-CMs exhibited phenotypes of early-stage IOC, including oxidative stress, arrhythmia, and contractile dysfunction.
• Iron-induced alterations in calcium kinetics were identified as critical in cardiomyocyte dysfunction.
• Ebselen, a divalent metal transporter 1 (DMT1) inhibitor and antioxidant, prevented iron overload phenotypes.
• The study supports a significant role for DMT1 in myocardial iron uptake.

Conclusions:

• Ebselen demonstrates potential as a preventive and therapeutic agent for IOC.
• Targeting DMT1 may offer a novel strategy for managing secondary iron overload.
• iPSC-CMs provide a valuable platform for studying IOC and screening therapeutic compounds.